Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASH 2021 | Role of transplant in MRD negativity

Natalie Callander • 13 Dec 2021
ASH 2021
Multiple Myeloma
FORTE MASTER

In this video, Natalie Callander, MD, University of Wisconsin School of Medicine and Public Health, Madison, WI, briefly shares some insights on minimal residual disease (MRD)-directed therapy, highlighting the impact of autologous stem cell transplant (ASCT) on MRD negativity rates in the MASTER trial (NCT03224507) and the FORTE trial (NCT02203643). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from Natalie Callander

The impact of daratumumab induction on stem cell collection in myeloma patients 0:46
The impact of daratumumab induction on stem cell collection in myeloma patients
Natalie Callander • 13 Dec 2021
DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma 2:22
DREAMM-5 sub-study: belamaf in combination with feladilimab in the treatment of R/R myeloma
Natalie Callander • 13 Dec 2021
Dara-KRd, transplant, and MRD response-adapted treatment in newly diagnosed myeloma 2:04
Dara-KRd, transplant, and MRD response-adapted treatment in newly diagnosed myeloma
Natalie Callander • 6 Sep 2021
MRD highlights from the IMW meeting 3:56
MRD highlights from the IMW meeting
Natalie Callander • 6 Sep 2021

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals